View Post

Positive Topline Survival Data Observed in Phase 3 Trial of SYD985 for HER2-Positive Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Matthew Fowler From: cancernetwork.com Data from the phase 3 TULIP trial showed that [vic-]trastuzumab duocarmazine yielded positive progression-free survival for patients with pretreated HER2-positive metastatic breast cancer. Positive topline results were observed in the phase 3 TULIP study (NCT03262935), which investigated the safety and efficacy of [vic-]trastuzumab duocarmazine (SYD985) compared with physician’s choice of chemotherapy in patients with pretreated …

View Post

New I-SPY 2 Trial Arm to Evaluate Byondis’ Antibody-Drug Conjugate in HER2-Low Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Dutch biopharmaceutical company Byondis (formerly Synthon Biopharmaceuticals) said on Monday that Quantum Leap, the company sponsoring the ongoing Phase II/III I-SPY 2 trial for subgroups of women with breast cancer, has selected Byondis’ antibody-drug conjugate SYD985 for inclusion in a new treatment arm of the study. Specifically, the new investigational arm of I-SPY 2, which …